The Effect of Sacubitril Valsartan on Liver and Kidney Function in Patients with Chronic Heart Failure
YAN Wei, YANG Xiao-lan, YANG Hao, KANG Li-ping, ZHANG Run-mei, LI Wen-juan, HUI Xing-wei
2023, 41(6):
8-11.
Asbtract
(
386 )
PDF (1981KB)
(
80
)
References |
Related Articles |
Metrics
Objective To observe the effect and influence of liver and kidney function of Sacubitril Valsartan in patients of chronic heart failure. Methods 200 patients with chronic heart failure who were treated or hospitalized in Tongchuan People's Hospital from January 2021 to December 2021 were collected as the subjects of this study. According to the method of random number table, they were divided into observation group and control group, 100 patients in each group, both groups were given diuretics, vasodilators, β-Receptor antagonists and other treatments. The observation group was treated with Sacubitril Valsartan on the basis of the above. The total effective rate, the liver and kidney functions and cardiac functions before and after treatment, and the incidence of adverse reactions after treatment of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group (P<0.05); there was no significant difference in Alt, AST, SCR and BUN levels between the two groups before treatment (P>0.05), after treatment, the Alt, AST, SCR and BUN levels of the two groups were decreased, and after treatment, the above indexes of the observation group were decreased, the range was greater than that of the control group (P<0.05); there was no significant difference in NT-proBNP levels between the two groups before treatment (P>0.05), after treatment, NT-proBNP levels in the two groups decreased on average, and after treatment, the decrease in the observation group was greater than that in the control group (P<0.05); there was no significant difference in the levels of LVEDD, LVESD, LVEF and 6MWT between the two groups before treatment (P>0.05), after treatment, the levels of LVEDD and LVESD in the two groups decreased, and the levels of LVEF and 6MWT increased on average, the improvement of the above indexes in the observation group was better than that in the control group (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of chronic heart failure patients with Sacubitril Valsartan can improve the treatment effect, promote the improvement of liver, kidney function and heart function, delay the progress of the disease, and it will not increase the adverse reactions.